Free US stock ESG scoring and sustainability analysis for responsible investing considerations. We evaluate environmental, social, and governance factors that increasingly impact long-term company performance.
Syndax Pharmaceuticals Inc. (SNDX), a clinical-stage biopharmaceutical company focused on oncology therapeutic development, is trading at a current price of $24.85 as of 2026-04-06, marking a 1.19% decline in its most recent trading session. This analysis examines key technical levels, recent market context, and potential near-term price scenarios for the stock, with no recent earnings data available for the company as of this writing. The analysis is focused exclusively on observed price action
Is Syndax Pharmaceuticals (SNDX) Stock Near Support | Price at $24.85, Down 1.19% - Shared Trade Alerts
SNDX - Stock Analysis
3256 Comments
1692 Likes
1
Breno
Influential Reader
2 hours ago
Free US stock valuation multiples and PEG ratio analysis to identify reasonably priced growth companies with attractive risk-reward profiles. Our valuation framework helps you find stocks with the right balance of growth and value characteristics for your portfolio. We provide P/E analysis, PEG ratios, and relative valuation metrics for comprehensive valuation coverage. Find value in growth with our comprehensive valuation analysis and multiples tools for growth at a reasonable price strategies.
π 58
Reply
2
Kevana
Power User
5 hours ago
Who else is thinking deeper about this?
π 54
Reply
3
Lurlie
Elite Member
1 day ago
Ah, regret not checking this earlier.
π 99
Reply
4
Yahna
New Visitor
1 day ago
Key indices are approaching resistance zones β monitor closely.
π 207
Reply
5
Kateleya
Legendary User
2 days ago
This feels like something Iβll regret later.
π 45
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.